MHRA (Medicines & Healthcare Products Regulatory Agency) updates UK situation after Boston extends recall
This article was originally published in Clinica
UK healthcare providers are to assess the validity of their stocks of Boston Scientific stent systems according to each product's use-by date, so as to correlate it to the manufacturing date, rather than cross-refer to the extensive list of product codes. So advises the Medicines and Healthcare products Regulatory Agency (MHRA), following the US company's August 5 worldwide update of recalls related to its Taxus paclitaxel-eluting stent and Express2 bare-metal stent systems (see this issue, page 16).
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.